This site is intended for health professionals only
Sunday 15 July 2018
Share |

Regulatory approval in Europe granted for glatiramer acetate 40mg/ml

Synthon has announced that it has successfully concluded the decentralised procedures for glatiramer acetate 40mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe.


Synthon received regulatory clearance in all 27 EU/EEA member states involved in the procedures. Granting of national marketing authorizations will follow in the near future.

Synthon’s 20mg/ml glatiramer acetate product has already received marketing authorisations in these European countries. As of the end of 2016, Synthon's partners have introduced glatiramer acetate 20mg/ml in the majority of these countries.


We are very pleased with this approval,” commented Synthon’s chief executive officer Jacques Lemmens. “It allows us to make an affordable version of the 40mg/ml dosage strength of glatiramer acetate available to MS patients in Europe.”

Ads by Google

You are leaving

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?


Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.



Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher